Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry-the Euro LEVO-LVAD study.

Abdelshafy, Mahmoud; Caliskan, Kadir; Simpkin, Andrew J; Elkoumy, Ahmed; Kimman, Jesse R; Elsherbini, Hagar; Elzomor, Hesham; de By, Theo M M H; Gollmann-Tepeköylü, Can; Berchtold-Herz, Michael; Loforte, Antonio; Reineke, David; Schoenrath, Felix; Paluszkiewicz, Lech; Gummert, Jan; Mohacsi, Paul; Meyns, Bart; Soliman, Osama (2023). Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry-the Euro LEVO-LVAD study. European journal of cardio-thoracic surgery, 63(5) Oxford University Press 10.1093/ejcts/ezad095

Preview

Text Efficacy_of_levosimendan_infusion_in_patients_undergoing_a_left_ventricular_assist_device_implant_in_a_propensity_score_matched_analysis_of_the_EUROMACS_registry-the_Euro_LEVO-LVAD_study.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (999kB) | Preview

OBJECTIVES

Early right-sided heart failure (RHF) was seen in 22% of recipients of a left ventricular assist device (LVAD) in the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). However, the optimal treatment of post-LVAD RHF is not well known. Levosimendan has proven to be effective in patients with cardiogenic shock and in those with end-stage heart failure. We sought to evaluate the efficacy of levosimendan on post-LVAD RHF and 30-day and 1-year mortality.

METHODS

The EUROMACS Registry was used to identify adults with mainstream continuous-flow LVAD implants who were treated with preoperative levosimendan compared to a propensity matched control cohort.

RESULTS

In total, 3661 patients received mainstream LVAD, of which 399 (11%) were treated with levosimendan pre-LVAD. Patients given levosimendan had a higher EUROMACS RHF score [4 (2- 5.5) vs 2 (2- 4); P < 0.001], received more right ventricular assist devices (RVAD) [32 (8%) vs 178 (5.5%); P = 0.038] and stayed longer in the intensive care unit post-LVAD implant [19 (8-35) vs 11(5-25); P < 0.001]. Yet, there was no significant difference in the rate of RHF, 30-day, or 1-year mortality. Also, in the matched cohort (357 patients taking levosimendan compared to an average of 622 controls across 20 imputations), we found no evidence for a difference in postoperative severe RHF, RVAD implant rate, length of stay in the intensive care unit or 30-day and 1-year mortality.

CONCLUSIONS

In this analysis of the EUROMACS registry, we found no evidence for an association between levosimendan and early RHF or death, albeit patients taking levosimendan had much higher risk profiles. For a definitive conclusion, a multicentre, randomized study is warranted.

Interest & Impact

Downloads

3 since deposited on 03 Jan 2024
3 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item